ATE339192T1 - Kontrollierte medikamentfreigabe zusammensetzung mit in vivo mechanikstresswiderstand - Google Patents

Kontrollierte medikamentfreigabe zusammensetzung mit in vivo mechanikstresswiderstand

Info

Publication number
ATE339192T1
ATE339192T1 AT04741578T AT04741578T ATE339192T1 AT E339192 T1 ATE339192 T1 AT E339192T1 AT 04741578 T AT04741578 T AT 04741578T AT 04741578 T AT04741578 T AT 04741578T AT E339192 T1 ATE339192 T1 AT E339192T1
Authority
AT
Austria
Prior art keywords
drug
release
vivo
matrix
present
Prior art date
Application number
AT04741578T
Other languages
English (en)
Inventor
Luigi Bruschi Stefano De
Sergio Pengo
Original Assignee
Eurand Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33446353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE339192(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eurand Pharmaceuticals Ltd filed Critical Eurand Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE339192T1 publication Critical patent/ATE339192T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
AT04741578T 2003-05-14 2004-05-14 Kontrollierte medikamentfreigabe zusammensetzung mit in vivo mechanikstresswiderstand ATE339192T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE20030366 2003-05-14

Publications (1)

Publication Number Publication Date
ATE339192T1 true ATE339192T1 (de) 2006-10-15

Family

ID=33446353

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04741578T ATE339192T1 (de) 2003-05-14 2004-05-14 Kontrollierte medikamentfreigabe zusammensetzung mit in vivo mechanikstresswiderstand

Country Status (7)

Country Link
US (1) US20070009596A1 (de)
EP (1) EP1628642B2 (de)
AT (1) ATE339192T1 (de)
DE (1) DE602004002405T3 (de)
ES (1) ES2273271T5 (de)
PL (1) PL1628642T3 (de)
WO (1) WO2004100932A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1847258T4 (da) † 2006-04-13 2013-04-15 Acino Pharma Ag Partialglycerider som smøremiddel til farmaceutiske sammensætninger indeholdende thieno[3,2-c]pyridin-derivater
CN101639471A (zh) * 2009-08-21 2010-02-03 天津中医药大学 一种用于评价药物固体制剂溶出/吸收过程的装置
WO2011090724A2 (en) * 2009-12-29 2011-07-28 Impax Laboratories, Inc. Gastroretentive solid oral dosage forms with lipid-based low-density excipient
WO2011146300A1 (en) * 2010-05-17 2011-11-24 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
CN105651822A (zh) * 2014-11-14 2016-06-08 湘潭大学 固体制剂活性物溶出性质的测试方法和测试装置
WO2025107056A1 (en) * 2023-11-23 2025-05-30 Sanofi Medley Farmaceutica Ltda Extended-release pharmaceutical composition and preparation process

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
ZA889189B (en) * 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
FR2656525A1 (fr) * 1989-12-29 1991-07-05 Delalande Sa Formes d'administration de medicament a liberation controlee et leur procede de fabrication.
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
AR030557A1 (es) † 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
GB0125088D0 (en) † 2001-10-18 2001-12-12 Smithkline Beecham Cork Ltd New use

Also Published As

Publication number Publication date
ES2273271T5 (es) 2013-05-21
WO2004100932A1 (en) 2004-11-25
EP1628642B2 (de) 2013-01-23
EP1628642A1 (de) 2006-03-01
ES2273271T3 (es) 2007-05-01
US20070009596A1 (en) 2007-01-11
DE602004002405D1 (de) 2006-10-26
DE602004002405T2 (de) 2007-09-06
DE602004002405T3 (de) 2013-06-20
PL1628642T3 (pl) 2007-01-31
EP1628642B1 (de) 2006-09-13

Similar Documents

Publication Publication Date Title
NO20075046L (no) Gastroresistente farmasoytiske formuleringer inneholdende rifaximin
WO2006076620A3 (en) Bendamustine pharmaceutical compositions for lyophilisation
EP4223316A3 (de) Verbessertes antikörper-oligonukleotid-konjugat
CY1111433T1 (el) Φαρμακευτικο τυποποιημενο παρασκευασμα δεσιταβινης
ECSP088239A (es) Composición de liberación de fármaco sostenida
MY152710A (en) Oral compositions containing extracts of garcinia mangostana l. and related methods
PE20080331A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
BRPI0608796B8 (pt) método para a preparação de um extrato de planta compreendendo bacuquiol
SV1999000118A (es) Nuevos derivados de pirazol substituidos ref. lea 33188-sv
WO2009073445A3 (en) Biocompatible biodegradable fumagillin analog conjugates
MXPA05002033A (es) Una composicion farmaceutica.
ECSP088240A (es) Composición de trazodona para administración una vez por día
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
MY149505A (en) Hyaluronic acid binary mixtures and therapeutic use thereof
DK1526840T3 (da) Nanopartikler til DNA administration til et målorgan
JP2011256136A (ja) コラーゲン分解阻害剤
MY147450A (en) Pharmaceutical combination
BRPI0518050A (pt) composição para debridamento a partir da bromelina e métodos para produção da mesma
BR0314898A (pt) Compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica
BRPI0417938A (pt) formulações de proteìnas hidrofóbicas em uma composição imunogênica que possui tolerabilidade aperfeiçoada
NO20034504L (no) Erytropoietin forbedrer in vivo kjemoterapiindusert toksisitet
ATE339192T1 (de) Kontrollierte medikamentfreigabe zusammensetzung mit in vivo mechanikstresswiderstand
MX2025009604A (es) Tetrazinas con propiedades mejoradas
NO20056000L (no) Vevsbeskyttende cytokiner for beskyttelse, gjenoppbygging og okning av responsivceller, vev og organer med et utvidet terapeutisk vindu
MD3905G2 (ro) Remediu medicamentos cu acţiune prelungită sub formă de gel pentru tratamentul afecţiunilor parodonţiului (variante)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties